Descartes 17
Alternative Names: Descartes-17Latest Information Update: 03 Jul 2023
At a glance
- Originator Cartesian Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued T-cell lymphoma
Most Recent Events
- 03 Jul 2023 Discontinued - Preclinical for T-cell lymphoma in USA (Parenteral) (Cartesian Therapeutics pipeline, July 2023)
- 05 Dec 2022 Descartes 17 is available for partnering as of 05 Dec 2022. https://www.cartesiantherapeutics.com/
- 05 Dec 2022 Preclinical trials in T-cell lymphoma in USA (Parenteral) (Cartesian Therapeutics, December 2022)